You are here

Herbert Smith Freehills advises sponsors on Peijia Medical’s HK$2.34 billion Hong Kong IPO / 史密夫斐尔律师事务所作为联席保荐人境外律师为沛嘉医疗23.4亿港元IPO提供法律服务

15 May 2020 | China
News

Share

Leading global law firm Herbert Smith Freehills has advised Morgan Stanley Asia Limited and Huatai Financial Holdings as joint sponsors of medical device manufacturer Peijia Medical Limited’s mainboard listing on the Stock Exchange of Hong Kong.

The IPO was over-subscribed by more than 1,100 times at the Hong Kong public offering and raised approximately HK$2.34 billion (US$302 million), and listed on 15 May 2020. The offering attracted 14 cornerstone investors that subscribed to shares worth HK$1.178 billion in total (US$151 million).

Herbert Smith Freehills has now advised on four biotech listings worth HK$7.856 billion in total since the Hong Kong exchange introduced its new regime for biotech listings in 2018.

“We are delighted to have advised Morgan Stanley and Huatai on this IPO,” said Hong Kong partner Matt Emsley. “Chinese biotech companies’ strong research and development and advanced products have fuelled the growth of this sector in China over the last decade.”

Peijia Medical produces replacement heart valve and vascular repair devices, vital for minimally invasive treatment of heart disease, aneurisms and stroke. Its products have been designed specifically for Chinese patients and healthcare providers.

“Peijia Medical is the 17th biotech listing on Hong Kong’s Main Board under the exchange’s relaxed biotech regime since it was introduced in 2018,” said Singapore partner Siddhartha Sivaramakrishnan, who advised on US securities law aspects of the offering.

“High-profile biotech listings continue to be attractive to the market due to their growing technical advantage and market potential.”

“The strong response to the IPO also demonstrates the biotech sector’s resilience to the market uncertainty of recent months,” said Herbert Smith Freehills Kewei joint operation partner Stanley Xie. “We congratulate Peijia Medical on its IPO, and look forward to its continued success.”

Partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie jointly led the team, assisted by senior associate Jin Kong, associates Maisie Ko, Jaime Fong, Tracy Lee and Sean Ji, trainees Samuel Au and Rachel Lam, and paralegal Hilary Chong and Jessica Sun.

 

国际知名的律师事务所史密夫斐尔作为医疗器械制造商沛嘉医疗有限公司联席保荐人摩根士丹利和华泰国际的境外律师,为其在香港联交所主板上市提供法律服务。

沛嘉医疗在首次公开募股中获得超1100倍认购,融资约23.4亿港元 (约合3.02亿美元),于2020年5月15日开始在香港联交所交易。其中,14位基石投资者认购金额约为11.78亿港元 (约合1.51亿美元)。

自香港联交所2018年推出生物技术公司上市新机制以来,史密夫斐尔已经为四家生物技术公司上市提供咨询,融资额达78.56亿港元。

史密夫斐尔香港办公室合伙人艾迈修 (Matt Emsley) 表示:“我们很高兴在此次IPO中为摩根士丹利和华泰国际提供法律服务。过去十年,中国生物技术公司凭借强大的研发能力和先进的产品推动了中国生物技术行业的飞速发展。”

沛嘉医疗生产经导管瓣膜治疗器械及神经介入手术器械,对于心脏病、动脉瘤和中风的微创治疗至关重要,并特别针对中国患者和临床应用。

史密夫斐尔新加坡办公室合伙人Siddhartha Sivaramakrishnan表示:“沛嘉医疗是港交所自2018年4月推出主板上市规则第18A章节、放宽生物技术公司上市条件以来,第17家按照该规则在港上市的生物技术公司。”

“备受瞩目的生物科技上市公司因其日益巩固的技术优势和巨大的市场潜力,对市场具有持续的吸引力。”

科伟史密夫斐尔联营办公室合伙人谢守德指出:“市场对沛嘉医疗的热烈反应显示出生物技术行业在近几个月充满不确定性的市场环境中所凸显出的韧性。衷心祝贺沛嘉医疗成功上市,并期待其取得更大发展。”

艾迈修、Siddhartha Sivaramakrishnan和谢守德率领律师团队为此次上市提供法律服务。主要团队成员包括孔瑾 (Senior Associate)、高美诗 (Associate)、方靖颐 (Associate)、利卓思 (Associate)、季晓源 (Associate)、区健聪 (Trainee)、林诺宜 (Trainee)、种欢子 (Paralegal) 以及孙菁 (Paralegal)。

Media Contact

For further information on this news article, please contact:

VIVIAN HUANG, COMMUNICATIONS MANAGER, CHINA

Beijing
Tel: 
+86 10 65355025

Sally Greig, Head of Communications, Asia

Hong Kong
Tel: 
+852 21014624